Delivery Order SPE2DB22D3004-SPE2DB25FQ75F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for EMGALITY 120 mg/mL in pen format, a migraine treatment medication. This firm fixed-price delivery order, issued on August 20, 2025, with an ultimate completion date of August 21, 2025, represents a small-value transaction under AmerisourceBergen's existing contract vehicle with DLA. The award was made on a competitive, non-set-aside basis, reflecting open competition in federal...
- The Defense Logistics Agency awarded a $1,583.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for EMGALITY 120 mg/mL pen/milliliter on September 3, 2025, with an ultimate completion date of September 4, 2025. This award represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. EMGALITY is a migraine treatment...
- The Defense Logistics Agency awarded a delivery order valued at $1,401.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen (injectable migraine treatment) with a completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract specifies performance at the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen, a migraine treatment medication. This competitively awarded, firm fixed-price delivery order was issued on August 8, 2025, with an ultimate completion date of August 11, 2025. The contract utilizes no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,114.74 to AmerisourceBergen Drug Corp for EMGALITY 120 mg/mL pen injectors, with an ultimate completion date of August 27, 2025. This non-competitive delivery order is issued under a firm fixed price arrangement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,805.48 to supply Emgality 120 mg/ml pen/ml, a migraine treatment medication. Awarded on August 6, 2025, with an ultimate completion date of August 7, 2025, this firm fixed-price delivery order represents a competitive award with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations. This...
- The Defense Logistics Agency awarded a delivery order valued at $2,074.80 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen/ml, a pharmaceutical product used in migraine treatment. This non-competitive, firm fixed-price delivery order was issued on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,074.80 firm fixed price delivery order for Emgality 120 mg/ml pen, a migraine treatment medication. Issued on August 1, 2025, this non-set-aside contract will be completed by August 4, 2025, with performance occurring at the contractor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX),...
- The Defense Logistics Agency awarded a delivery order valued at $1,729.00 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen/mL, a pharmaceutical product used in migraine treatment. The contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, using firm fixed pricing with no set-aside designation. Performance will occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the pharmaceutical product Emgality 120 mg/mL pen on May 20, 2025, with a ceiling value of $1,037.40. This firm fixed-price contract is non-competitive and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle valued through December 2026. The place of performance is...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FQ75FDelivery Order
The Defense Logistics Agency awarded a $1,729.00 delivery order to AmerisourceBergen Drug Corp for EMGALITY 120 MG/ML PENML, a migraine treatment medication, with a completion date of September 17, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, was selected to supply this specialty pharmaceutical product to support military and federal healthcare systems. This delivery order represents a child contract under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs worldwide. The company's extensive portfolio of federal medical supply contracts demonstrates its capability to fulfill diverse pharmaceutical procurement requirements across multiple therapeutic domains for the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 9/16/25 |